Stay updated on Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov record for a completed tildrakizumab extension study in psoriatic arthritis is available, with its study methods, participant criteria, locations, outcomes, and record documents.SummaryDifference76%

- Check11 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA site-wide banner announces an NIH terminology transition, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check53 days agoChange DetectedRemoved key study documents and metadata from the record, including PDFs and location/arm information, thereby altering the materials and context available for the long-term extension study.SummaryDifference18%

- Check60 days agoChange DetectedThe page's underlying platform version was upgraded from v3.6.6 to v3.7.0, representing a software update.SummaryDifference0.0%

Stay in the know with updates to Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.